Scholar Rock Announces Presentation of New Preclinical Data Evaluating SRK-439 in Obesity at Keystone Symposia
Scholar Rock will present preclinical data evaluating SRK-439 in combination with GLP-1 receptor agonists in obesity to maintain lean mass and enhance fat mass loss.
- Scholar Rock will present preclinical data evaluating SRK-439 in combination with GLP-1 receptor agonists in obesity to maintain lean mass and enhance fat mass loss.
- “Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as effective treatments with rapid implementation for obesity, a recognized global epidemic.
- However, the weight loss resulting from GLP-1 RA treatment has been shown to be associated with significant loss of lean muscle mass.
- The presentation will be made available in the Publications & Posters section of Scholar Rock’s website following the presentation.